Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulation… Read more
Canntab Therapeutics Limited (CTABF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of February 2023: 0.017x
Based on the latest financial reports, Canntab Therapeutics Limited (CTABF) has a cash flow conversion efficiency ratio of 0.017x as of February 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.69K) by net assets ($-2.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Canntab Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2011–2022)
This chart illustrates how Canntab Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Canntab Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Canntab Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hansol Homedeco Co. Ltd.
KQ:025750
|
N/A |
|
Fable Media Group AB
ST:FABLE
|
N/A |
|
Detalion Games S.A.
WAR:DEG
|
N/A |
|
North PetroVietnam Fertilizer & Chemicals JSC
VN:PMB
|
N/A |
|
CWWGF
PINK:CWWGF
|
N/A |
|
COMPAGNIE IMMOBILI
SEM:CIMO
|
N/A |
|
CAP LEASE AVIATION
LSE:CLA
|
-0.046x |
|
TOTALENERGIES MARKETING NIGERIA PLC
XNSA:TOTAL
|
N/A |
Annual Cash Flow Conversion Efficiency for Canntab Therapeutics Limited (2011–2022)
The table below shows the annual cash flow conversion efficiency of Canntab Therapeutics Limited from 2011 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-05-31 | $-311.22K | $-2.85 Million | 9.144x | +828.07% |
| 2021-05-31 | $2.27 Million | $-2.85 Million | -1.256x | -133.33% |
| 2020-05-31 | $3.53 Million | $-1.90 Million | -0.538x | +47.68% |
| 2019-05-31 | $2.27 Million | $-2.33 Million | -1.029x | -248.84% |
| 2018-05-31 | $4.30 Million | $-1.27 Million | -0.295x | -137.91% |
| 2017-12-31 | $-147.60K | $-114.81K | 0.778x | +327.68% |
| 2017-05-31 | $1.04 Million | $-354.81K | -0.342x | -105.44% |
| 2016-12-31 | $-65.16K | $-408.93K | 6.276x | +2391.56% |
| 2016-05-31 | $940.23K | $-257.50K | -0.274x | +64.40% |
| 2015-05-31 | $39.18K | $-30.14K | -0.769x | +68.24% |
| 2014-05-31 | $215.05K | $-520.85K | -2.422x | +77.73% |
| 2013-05-31 | $120.53K | $-1.31 Million | -10.876x | -488.35% |
| 2012-05-31 | $581.44K | $-1.07 Million | -1.849x | -2330.41% |
| 2011-05-31 | $728.59K | $-55.42K | -0.076x | -- |